
Sign up to save your podcasts
Or


In this week's episode we’ll discuss the findings from a prospective trial of brentuximab vedotin with dacarbazine or nivolumab in older patients with classical Hodgkin lymphoma, learn more about CD20 antigen loss as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas, and discuss the role of trogocytosis in red blood cell antigen loss.
By American Society of Hematology4.1
4949 ratings
In this week's episode we’ll discuss the findings from a prospective trial of brentuximab vedotin with dacarbazine or nivolumab in older patients with classical Hodgkin lymphoma, learn more about CD20 antigen loss as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas, and discuss the role of trogocytosis in red blood cell antigen loss.

11,147 Listeners

140 Listeners

318 Listeners

499 Listeners

75 Listeners

26 Listeners

1,157 Listeners

2 Listeners

363 Listeners

373 Listeners

1 Listeners

48 Listeners

190 Listeners

30 Listeners

4 Listeners